{
  "id": 1768038,
  "title": "Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?",
  "url": "https://urgent.news/2026/08/18/which-healthcare-etf-is-the-better-buy-vanecks-pharma-pph-or-state",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T17:42:50.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/coverage/etfs/2026/08/18/which-healthcare-etf-is-the-better-buy-vaneck-s-pharma-pph-or-state-street-s-biotech-xbi/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "When considering which healthcare ETF to invest in, two prominent options stand out: VanEck's Pharma PPH and State Street's Biotech XBI. Both funds offer exposure to the healthcare sector, but cater to different investment strategies.\n\nPPH provides focused exposure to established global drugmakers, offering investors the stability and cash flows associated with large pharmaceutical companies. This fund attracts those seeking a more conservative approach to healthcare investments.\n\nOn the other hand, XBI offers a diversified play on smaller-cap biotechnology innovation. With a higher-volatility profile, this ETF is designed for investors who are comfortable with greater risk for the potential of higher returns. It captures the high-reward nature of early-stage biotech research, targeting companies with promising pipelines and growth potential.\n\nWhen evaluating these ETFs, it's essential to consider key metrics. The beta measures the fund's price volatility relative to the S&P 500, calculated from monthly returns over the available fund history, up to five years. The 1-year return represents the total return over the trailing 12 months, providing insight into recent performance. Additionally, the dividend yield reflects the trailing-12-month distribution yield, indicating income potential.\n\nUltimately, the choice between PPH and XBI depends on an investor's strategy and risk tolerance. Those seeking stability and income from well-established pharmaceutical giants may favor PPH, while those comfortable with higher risk in pursuit of potentially greater rewards may opt for XBI. Careful consideration of these factors is crucial in determining which ETF aligns best with an individual's investment goals.",
  "summary": "PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?",
        "url": "https://urgent.news/2026/08/18/which-healthcare-etf-is-the-better-buy-vanecks-pharma-pph-or-state-1770001",
        "published": "2026-08-18T18:02:50.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}